{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:47:05Z","timestamp":1790801225359,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"publisher","award":["TUMS 96-01-103-34328"],"award-info":[{"award-number":["TUMS 96-01-103-34328"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["MUMS 961630"],"award-info":[{"award-number":["MUMS 961630"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021077","name":"Vice Chancellor for Research and Technology, Kerman University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.lfs.2022.120920","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T09:34:39Z","timestamp":1661679279000},"page":"120920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Selective APC-targeting of a novel Fc-fusion multi-immunodominant recombinant protein (tTax-tEnv:mFc\u03b32a) for HTLV-1 vaccine development"],"prefix":"10.1016","volume":"308","author":[{"given":"Mina","family":"Shafifar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4570-2252","authenticated-orcid":false,"given":"Sayed-Hamidreza","family":"Mozhgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-8069","authenticated-orcid":false,"given":"Kobra","family":"Razavi Pashabayg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8408-4664","authenticated-orcid":false,"given":"Arman","family":"Mosavat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9899-2885","authenticated-orcid":false,"given":"Mohsen","family":"Karbalaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Norouzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6814-5992","authenticated-orcid":false,"given":"Seyed Abdolrahim","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.120920_bb0005","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1128\/jvi.69.10.6077-6089.1995","article-title":"Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction","volume":"69","author":"Lairmore","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2022.120920_bb0010","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0264-410X(00)00340-6","article-title":"Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide","volume":"19","author":"Frangione-Beebe","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2022.120920_bb0015","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/jnci\/93.23.1775","article-title":"Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: peptide-induced T-cell immunity","volume":"93","author":"Hanabuchi","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.lfs.2022.120920_bb0020","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1128\/JVI.75.13.5939-5948.2001","article-title":"Immunogenicity and protective efficacy of recombinant human T-cell leukemia\/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus)","volume":"75","author":"Kazanji","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2022.120920_bb0025","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0264-410X(01)00478-9","article-title":"New approach for generation of neutralising antibody against human T-cell leukaemia virus type-I (HTLV-I) using phage clones","volume":"20","author":"Begum","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2022.120920_bb0030","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1128\/JVI.77.5.2956-2963.2003","article-title":"Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response","volume":"77","author":"Hasegawa","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2022.120920_bb0035","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1016\/S0264-410X(03)00179-8","article-title":"A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design","volume":"21","author":"Sundaram","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2022.120920_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1399-3011.2003.00113.x","article-title":"Structural and immunogenicity analysis of chimeric B-cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV-1","volume":"63","author":"Sundaram","year":"2004","journal-title":"J. Pept. Res."},{"key":"10.1016\/j.lfs.2022.120920_bb0045","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/00126334-200411010-00001","article-title":"Protective efficacy of multiepitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus","volume":"37","author":"Sundaram","year":"2004","journal-title":"J Acquir Immune Defic Syndr."},{"key":"10.1016\/j.lfs.2022.120920_bb0050","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1158\/1078-0432.CCR-06-0384","article-title":"In vitro peptide immunisation of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes","volume":"12","author":"Kobayashi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2022.120920_bb0055","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1099\/vir.0.81582-0","article-title":"Chimeric peptide vaccine composed of B- and T-cell epitopes of human T-cell leukemia virus type 1 induces humoral and cellular immune responses and reduces the proviral load in immunised squirrel monkeys (Saimiri sciureus)","volume":"87","author":"Kazanji","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.lfs.2022.120920_bb0060","first-page":"179","article-title":"Human T lymphotropic virus type I (HTLV-I) oncogenesis: molecular aspects of virus and host interactions in pathogenesis of adult T cell Leukemia\/Lymphoma (ATL)","volume":"16","author":"Ahmadi Ghezeldasht","year":"2013","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.lfs.2022.120920_bb0065","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.virol.2012.09.028","article-title":"HTLV-1: persistence and pathogenesis","volume":"435","author":"Cook","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.lfs.2022.120920_bb0070","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/sj.bjc.6605345","article-title":"Mechanisms of HTLV-1 persistence and transformation","volume":"101","author":"Boxus","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2022.120920_bb0075","first-page":"153","article-title":"HTLV-I infection: virus structure, immune response to the virus and genetic association studies in HTLV-I-infected individuals","volume":"5","author":"Rafatpanah","year":"2006","journal-title":"Iran J. Allergy Asthma Immunol."},{"key":"10.1016\/j.lfs.2022.120920_bb0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3389\/fmicb.2013.00328","article-title":"Mechanisms of pathogenesis induced by bovine leukemia virus as a model for human T-cell leukemia virus","volume":"4","author":"Aida","year":"2013","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lfs.2022.120920_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1532\/IJH97.07092","article-title":"Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia","volume":"86","author":"Kannagi","year":"2007","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.lfs.2022.120920_bb0090","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molimm.2009.09.006","article-title":"Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia","volume":"47","author":"Kozako","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.lfs.2022.120920_bb0095","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1742-4658.2011.08055.x","article-title":"Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant","volume":"278","author":"Kozako","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.lfs.2022.120920_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.1100070","article-title":"Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralise viral infectivity at multiple steps of the entry process","volume":"187","author":"Kuo","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2022.120920_bb0105","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00262-012-1284-7","article-title":"A naturally processed HLA-DR-bound peptide from the IL-9 receptor alpha of HTLV-1-transformed T cells serves as a T helper epitope","volume":"61","author":"Kobayashi","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2022.120920_bb0110","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.vaccine.2014.03.087","article-title":"In vivo immunogenicity of Tax(11\u201319) epitope in HLA-A2\/DTR transgenic mice: implication for dendritic cell-based anti-HTLV-1 vaccine","volume":"32","author":"Sagar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2022.120920_bb0115","first-page":"453","article-title":"Immunisation of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4","volume":"48","author":"Kampylafka","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.lfs.2022.120920_bb0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.micpath.2016.05.012","article-title":"Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46","volume":"97","author":"Amirnasr","year":"2016","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.lfs.2022.120920_bb0125","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijpharm.2018.07.069","article-title":"The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1","volume":"549","author":"Kabiri","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2022.120920_bb0130","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/cas.13948","article-title":"Maintenance of long remission in adult T-cell leukemia by tax-targeted vaccine: a hope for disease-preventive therapy","volume":"110","author":"Kannagi","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lfs.2022.120920_bb0135","first-page":"8","article-title":"40 years of the human T-cell leukemia virus: past, present, and future","author":"Tagaya","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.lfs.2022.120920_bb0140","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.lfs.2022.120920_bb0145","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1186\/s12885-018-5209-5","article-title":"HTLV-1-host interactions on the development of adult T cell leukemia\/lymphoma: virus and host gene expressions","volume":"18","author":"Tarokhian","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lfs.2022.120920_bb0150","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/intimm\/3.8.761","article-title":"Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells","volume":"3","author":"Kannagi","year":"1991","journal-title":"Int. Immunol."},{"key":"10.1016\/j.lfs.2022.120920_bb0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12977-019-0484-z","article-title":"Impact of host immunity on HTLV-1 pathogenesis: potential of tax-targeted immunotherapy against ATL","volume":"16","author":"Kannagi","year":"2019","journal-title":"Retrovirology"},{"key":"10.1016\/j.lfs.2022.120920_bb0160","first-page":"16","article-title":"Predicting and designing epitope ensemble vaccines against HTLV-1","author":"Alam","year":"2020","journal-title":"J Integr Bioinform."},{"key":"10.1016\/j.lfs.2022.120920_bb0165","doi-asserted-by":"crossref","first-page":"7609","DOI":"10.1128\/JVI.72.9.7609-7614.1998","article-title":"Analysis of functional conservation in the surface and transmembrane glycoprotein subunits of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2","volume":"72","author":"Rosenberg","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2022.120920_bb0170","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1128\/jvi.66.10.5879-5889.1992","article-title":"Mapping of homologous, amino-terminal neutralising regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins","volume":"66","author":"Palker","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2022.120920_bb0175","first-page":"179","article-title":"Human T lymphotropic virus type I (HTLV-I) oncogenesis: molecular aspects of virus and host interactions in pathogenesis of adult T cell leukemia\/lymphoma (ATL)","volume":"16","author":"Ghezeldasht","year":"2013","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.lfs.2022.120920_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/478461","article-title":"Immunogenetics and the pathological mechanisms of human T-cell leukemia VirusType 1- (HTLV-1-)Associated Myelopathy\/Tropical spastic paraparesis (HAM\/TSP)","volume":"2010","author":"Saito","year":"2010","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"10.1016\/j.lfs.2022.120920_bb0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.virol.2010.04.018","article-title":"Activation of the PI3K-Akt pathway by human T cell leukemia virus type 1 (HTLV-1) oncoprotein Tax increases Bcl3 expression, which is associated with enhanced growth of HTLV-1-infected T cells","volume":"403","author":"Saito","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.lfs.2022.120920_bb0190","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/onc.2010.537","article-title":"Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy","volume":"30","author":"Matsuoka","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2022.120920_bb0195","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1128\/JVI.01241-10","article-title":"Adjuvant-free immunisation with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines","volume":"85","author":"Loureiro","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2022.120920_bb0200","doi-asserted-by":"crossref","first-page":"10542","DOI":"10.1128\/JVI.05441-11","article-title":"A neonatal fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection","volume":"85","author":"Lu","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2022.120920_bb0205","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/j.vaccine.2011.01.113","article-title":"Ebola virus glycoprotein fc fusion protein confers protection against lethal challenge in vaccinated mice","volume":"29","author":"Konduru","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2022.120920_bb0210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/07388551.2016.1163323","article-title":"Fcgamma1 fragment of IgG1 as a powerful affinity tag in recombinant fc-fusion proteins: immunological, biochemical and therapeutic properties","volume":"37","author":"Soleimanpour","year":"2017","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.lfs.2022.120920_bb0215","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.meegid.2016.01.027","article-title":"Fused mycobacterium tuberculosis multi-stage immunogens with an fc-delivery system as a promising approach for the development of a tuberculosis vaccine","volume":"39","author":"Mosavat","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.lfs.2022.120920_bb0220","doi-asserted-by":"crossref","first-page":"10467","DOI":"10.1007\/s00253-015-6952-z","article-title":"APC targeting enhances immunogenicity of a novel multi-stage fc-fusion tuberculosis vaccine in mice","volume":"99","author":"Soleimanpour","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.lfs.2022.120920_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lfs.2018.09.031","article-title":"HTLV-1 infection-induced motor dysfunction, memory impairment, depression, and brain tissues oxidative damage in female BALB\/c mice","volume":"212","author":"SRR","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2022.120920_bb0230","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1128\/JVI.73.2.1205-1212.1999","article-title":"The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes","volume":"73","author":"Hadlock","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.lfs.2022.120920_bb0235","doi-asserted-by":"crossref","first-page":"24141","DOI":"10.1074\/jbc.M313210200","article-title":"De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralising antibodies","volume":"279","author":"Sundaram","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2022.120920_bb0240","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1038\/sj.onc.1208970","article-title":"Cellular immune response to HTLV-1","volume":"24","author":"Bangham","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2022.120920_bb0245","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1016\/j.vaccine.2018.07.002","article-title":"In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection","volume":"36","author":"Mulherkar","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2022.120920_bb0250","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3390\/v2071427","article-title":"The HTLV-1 virological synapse","volume":"2","author":"Nejmeddine","year":"2010","journal-title":"Viruses."},{"key":"10.1016\/j.lfs.2022.120920_bb0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0042-6822(91)90654-T","article-title":"Limited sequence variation in human T-lymphotropic virus type 1 isolates from north american and african patients","volume":"182","author":"Paine","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.lfs.2022.120920_bb0260","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4049\/jimmunol.142.3.971","article-title":"Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46","volume":"142","author":"Palker","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2022.120920_bb0265","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2672.2009.04279.x","article-title":"Efficient generation of multi-copy strains for optimising secretory expression of porcine insulin precursor in yeast Pichia pastoris","volume":"107","author":"Zhu","year":"2009","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.lfs.2022.120920_bb0270","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1002\/jcp.29583","article-title":"Pichia pastoris: a highly successful expression system for optimal synthesis of heterologous proteins","volume":"235","author":"Karbalaei","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.lfs.2022.120920_bb0275","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/BA20060170","article-title":"Comparative expression of different antibody formats in mammalian cells and Pichia pastoris","volume":"47","author":"Braren","year":"2007","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.lfs.2022.120920_bb0280","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/erv.09.160","article-title":"Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists","volume":"9","author":"Black","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2022.120920_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107669","article-title":"An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) focusing on clinical and laboratory biomarkers","volume":"218","author":"Yamauchi","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2022.120920_bb0290","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s002620050418","article-title":"Increased potency of fc-receptor-targeted antigens","volume":"45","author":"Guyre","year":"1997","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2022.120920_bb0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tibtech.2014.11.001","article-title":"Fc fusion as a platform technology: potential for modulating immunogenicity","volume":"33","author":"Levin","year":"2015","journal-title":"Trends Biotechnol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522006208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522006208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:02:25Z","timestamp":1758402145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522006208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":59,"alternative-id":["S0024320522006208"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120920","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective APC-targeting of a novel Fc-fusion multi-immunodominant recombinant protein (tTax-tEnv:mFc\u03b32a) for HTLV-1 vaccine development","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120920"}}